Alnylam to Webcast Presentation at Stifel 3rd Annual CNS Day
Alnylam Pharmaceuticals (Nasdaq: ALNY) will present a company overview at the Stifel 3rd Annual CNS Day on April 1, 2021, at 11:00 am ET. A live audio webcast will be accessible via the Investors section of Alnylam's website, with a replay available within 48 hours. Alnylam is a leader in RNA interference therapeutics, focusing on innovative medicines for rare genetic and CNS diseases. They have launched products like ONPATTRO and are advancing multiple investigational medicines under the Alnylam P5x25 strategy.
- None.
- None.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 3rd Annual CNS Day on Thursday, April 1, 2021 at 11:00 am ET.
A live audio webcast of the presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.
About Alnylam
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO™ (lumasiran) and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005390/en/
FAQ
When will Alnylam Pharmaceuticals present at the Stifel 3rd Annual CNS Day?
How can I listen to Alnylam Pharmaceuticals' presentation?
What is Alnylam Pharmaceuticals known for?
What products has Alnylam Pharmaceuticals launched?
What is the Alnylam P5x25 strategy?
